演題詳細

一般口演 / Oral Session

一般口演 11 (Oral Session 11) :低悪性度B細胞リンパ腫:治療研究

print

日程
2013年10月11日(金)
時間
09:30 - 10:30
会場
第8会場 / Room No.8 (ロイトン札幌 2F ハイネス)
座長・司会
小宅 達郎 (Tatsuo Oyake):1
1:岩手医科大学 血液・腫瘍内科
 
前へ戻る

Rituximab induction and maintenance for low grade B cell lymphoma: A multicenter, phase II study

演題番号 : OS-1-51

松本 守生 (Morio Matsumoto):1,2、下村 壮司 (Souji Shimomura):2,4、竹内 誠 (Makoto Takeuchi):2,5、花田 修一 (Shuichi Hanada):2,6、米野 琢哉 (Takuya Komeno):2,7、角南 一貴 (Kazutaka Sunami):2,8、日高 道弘 (Michihiro Hidaka):2,9、矢野 尊啓 (Takahiro Yano):2,10、北野 喜良 (Kiyoshi Kitano):2,11、吉田 功 (Isao Yoshida):2,12、井上 信正 (Nobumasa Inoue):2,13、堀部 敬三 (Keizo Horibe):2,3、澤村 守夫 (Morio Sawamura):1,2、渡邉 智之 (Tomoyuki Watanabe):2,14、永井 宏和 (Hirokazu Nagai):2,3

1:Department of Hematology, NHO Nishigunma National Hospital, Shibukawa, Japan、2:Clinical Hematology Group of National Hospital Organization (CHG-NHO)、3:National Hospital Organization Naogoya Medical Center, Nagoya, Japan、4:National Hospital Organization Hiroshima-nishi Medical Center, Otake, Japan、5:National Hospital Organization Minami-Okayama Medical Center, Tsukubo, Japan、6:National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan、7:National Hospital Organization Mito Medical Center, Mito, Japan、8:National Hospital Organization Okayama Medical Center, Okayama, Japan、9:National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan、10:National Hospital Organization Tokyo Medical Center, Tokyo, Japan、11:National Hospital Organization Matsumoto Medical Center, Matsumoto, Japan、12:National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan、13:National Hospital Organization Osaka Medical Center, Osaka Japan、14:Aichi Gakuin University, Nisshin, Japan

 

Introduction: Rituximab has markedly improved the clinical outcomes of mature B cell lymphoma, and rituximab maintenance therapy has been shown to be beneficial, especially in low grade B cell lymphoma (LGBCL). A multicenter, phase II trial was conducted to evaluate the efficacy and safety of rituximab as induction and maintenance therapy for LGBCL. Patients and Methods: Patients with LGBCL without prior rituximab treatment received rituximab (375 mg/m2) weekly for 8 weeks as induction therapy, and then patients who did not have progressive disease at the end of induction received maintenance therapy with 4 weeks of rituximab at six-month intervals (up to 2 years or disease progression). The primary endpoint was the best response rate. Results: Forty-one patients with a median age of 64 years (41 to 79) were enrolled at 12 institutes belonging to the Clinical Hematology Group of National Hospital Organization (CHG-NHO) from December 2005 to May 2009. The majority of disease histology was follicular lymphoma in 33 patients. Of the 41 patients, 31 (75.6%) completed the planned 2-years maintenance therapy. The overall response rate was 75.6% (31/41, 90% CI: 62.2-86.1%), with 63.4% CR. Three-year PFS at a median follow-up time of 43.0 months (5.3-72) was 79.7% (90%CI, 66.6-88.1%). Grade 3 toxicities were neutropenia in 2.5% (1/41), elevated ALT in 2.5% (1/41), and infection in 2.5% (1/41). There was no grade 4 toxicity. Conclusions: Rituximab induction and maintenance therapy was demonstrated to have high activity, with durable PFS and minimum toxicity in LGBCL patients.

前へ戻る